|
Sex
|
M:F = 11/15
|
M:F = 15/31
|
n.s.
|
|
Median age at diagnosis (years)
|
43 (20–87)
|
61 (27–83)
|
p = 0.019
|
|
WBC at diagnosis (109/l)
|
9100
|
8745
|
n.s.
|
|
Hb at diagnosis (g/dl)
|
14.6
|
14.3
|
n.s.
|
|
PLT at diagnosis (109/l)
|
825000
|
797500
|
n.s.
|
|
Increased LDH
|
6/19 (31.6%)
|
19/31 (61.3%)
|
n.s.
|
|
Splenomegaly (%)
|
6 (23%)
|
12 (26%)
|
n.s.
|
|
JAK2V617-positive (%)
|
9 (50%)
|
14 (58%)
|
n.s.
|
|
History of thrombosis (%)
|
6 (23%)
|
10 (22%)
|
n.s.
|
|
Thrombosis at diagnosis (%)
|
4 (15%)
|
7 (15%)
|
n.s.
|
|
Thrombotic events during follow-up (%)
|
6 (23%)
|
5 (10%)
|
n.s.
|
|
Progression to overt MF (%)
|
0 (0%)
|
3 (6.5%)
|
n.s.
|
|
Dead/Alive
|
2/24
|
6/40
|
n.s.
|
|
Conventional Risk (Low/High)
|
13/13
|
17/29
|
n.s.
|
|
Cytoreductive therapy (%)
|
24 (92%)
|
40 (86%)
|
n.s.
|
